This guideline covers identifying and managing depression in adults aged 18 years and older, in primary and secondary care. It aims to improve care for people with depression by promoting improved recognition and treatment.
MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place. This is because of the risk of malformations and developmental abnormalities in the baby. See update information for details. In March 2019, we produced a summary of NICE guidance to support the safe use of valproate.
NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).
This guideline includes recommendations on:
This guideline updates and replaces NICE guideline CG23 (December 2004).